These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 36332622)

  • 1. FOXA2 drives lineage plasticity and KIT pathway activation in neuroendocrine prostate cancer.
    Han M; Li F; Zhang Y; Dai P; He J; Li Y; Zhu Y; Zheng J; Huang H; Bai F; Gao D
    Cancer Cell; 2022 Nov; 40(11):1306-1323.e8. PubMed ID: 36332622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone demethylase PHF8 drives neuroendocrine prostate cancer progression by epigenetically upregulating FOXA2.
    Liu Q; Pang J; Wang LA; Huang Z; Xu J; Yang X; Xie Q; Huang Y; Tang T; Tong D; Liu G; Wang L; Zhang D; Ma Q; Xiao H; Lan W; Qin J; Jiang J
    J Pathol; 2021 Jan; 253(1):106-118. PubMed ID: 33009820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate.
    Park JW; Lee JK; Witte ON; Huang J
    Mod Pathol; 2017 Sep; 30(9):1262-1272. PubMed ID: 28621319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression and role of Foxa proteins in prostate cancer.
    Mirosevich J; Gao N; Gupta A; Shappell SB; Jove R; Matusik RJ
    Prostate; 2006 Jul; 66(10):1013-28. PubMed ID: 16001449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOXA2 rewires AP-1 for transcriptional reprogramming and lineage plasticity in prostate cancer.
    Wang Z; Townley SL; Zhang S; Liu M; Li M; Labaf M; Patalano S; Venkataramani K; Siegfried KR; Macoska JA; Han D; Gao S; Risbridger GP; Taylor RA; Lawrence MG; He HH; Selth LA; Cai C
    Nat Commun; 2024 Jun; 15(1):4914. PubMed ID: 38851846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.
    Singh N; Ramnarine VR; Song JH; Pandey R; Padi SKR; Nouri M; Olive V; Kobelev M; Okumura K; McCarthy D; Hanna MM; Mukherjee P; Sun B; Lee BR; Parker JB; Chakravarti D; Warfel NA; Zhou M; Bearss JJ; Gibb EA; Alshalalfa M; Karnes RJ; Small EJ; Aggarwal R; Feng F; Wang Y; Buttyan R; Zoubeidi A; Rubin M; Gleave M; Slack FJ; Davicioni E; Beltran H; Collins C; Kraft AS
    Nat Commun; 2021 Dec; 12(1):7349. PubMed ID: 34934057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and Biological Features of Neuroendocrine Prostate Cancer.
    Yamada Y; Beltran H
    Curr Oncol Rep; 2021 Jan; 23(2):15. PubMed ID: 33433737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reprogramming hormone-sensitive prostate cancer to a lethal neuroendocrine cancer lineage by mitochondrial pyruvate carrier (MPC).
    Xu H; Liu Z; Gao D; Li P; Shen Y; Sun Y; Xu L; Song N; Wang Y; Zhan M; Gao X; Wang Z
    Mol Metab; 2022 May; 59():101466. PubMed ID: 35219875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer.
    Yasumizu Y; Rajabi H; Jin C; Hata T; Pitroda S; Long MD; Hagiwara M; Li W; Hu Q; Liu S; Yamashita N; Fushimi A; Kui L; Samur M; Yamamoto M; Zhang Y; Zhang N; Hong D; Maeda T; Kosaka T; Wong KK; Oya M; Kufe D
    Nat Commun; 2020 Jan; 11(1):338. PubMed ID: 31953400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-transcriptional Gene Regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate Cancer.
    Fernandes RC; Toubia J; Townley S; Hanson AR; Dredge BK; Pillman KA; Bert AG; Winter JM; Iggo R; Das R; Obinata D; ; Sandhu S; Risbridger GP; Taylor RA; Lawrence MG; Butler LM; Zoubeidi A; Gregory PA; Tilley WD; Hickey TE; Goodall GJ; Selth LA
    Cell Rep; 2021 Jan; 34(1):108585. PubMed ID: 33406413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Epigenetic Change in Therapy-Induced Neuroendocrine Prostate Cancer Lineage Plasticity.
    Storck WK; May AM; Westbrook TC; Duan Z; Morrissey C; Yates JA; Alumkal JJ
    Front Endocrinol (Lausanne); 2022; 13():926585. PubMed ID: 35909568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mash1 expression is induced in neuroendocrine prostate cancer upon the loss of Foxa2.
    Gupta A; Yu X; Case T; Paul M; Shen MM; Kaestner KH; Matusik RJ
    Prostate; 2013 May; 73(6):582-9. PubMed ID: 23060003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroendocrine differentiation in the 12T-10 transgenic prostate mouse model mimics endocrine differentiation of pancreatic beta cells.
    Gupta A; Wang Y; Browne C; Kim S; Case T; Paul M; Wills ML; Matusik RJ
    Prostate; 2008 Jan; 68(1):50-60. PubMed ID: 18004726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MCTP1 increases the malignancy of androgen-deprived prostate cancer cells by inducing neuroendocrine differentiation and EMT.
    Liu YN; Chen WY; Yeh HL; Chen WH; Jiang KC; Li HR; Dung PVT; Chen ZQ; Lee WJ; Hsiao M; Huang J; Wen YC
    Sci Signal; 2024 Jun; 17(840):eadc9142. PubMed ID: 38861615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel mechanism of SRRM4 in promoting neuroendocrine prostate cancer development via a pluripotency gene network.
    Lee AR; Gan Y; Tang Y; Dong X
    EBioMedicine; 2018 Sep; 35():167-177. PubMed ID: 30100395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The β
    Braadland PR; Ramberg H; Grytli HH; Urbanucci A; Nielsen HK; Guldvik IJ; Engedal A; Ketola K; Wang W; Svindland A; Mills IG; Bjartell A; Taskén KA
    Mol Cancer Res; 2019 Nov; 17(11):2154-2168. PubMed ID: 31395667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FOXA1 inhibits prostate cancer neuroendocrine differentiation.
    Kim J; Jin H; Zhao JC; Yang YA; Li Y; Yang X; Dong X; Yu J
    Oncogene; 2017 Jul; 36(28):4072-4080. PubMed ID: 28319070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen-targeted therapies.
    Zaidi S; Park J; Chan JM; Roudier MP; Zhao JL; Gopalan A; Wadosky KM; Patel RA; Sayar E; Karthaus WR; Kates DH; Chaudhary O; Xu T; Masilionis I; Mazutis L; Chaligné R; Obradovic A; Linkov I; Barlas A; Jungbluth AA; Rekhtman N; Silber J; Manova-Todorova K; Watson PA; True LD; Morrissey C; Scher HI; Rathkopf DE; Morris MJ; Goodrich DW; Choi J; Nelson PS; Haffner MC; Sawyers CL
    Proc Natl Acad Sci U S A; 2024 Jul; 121(28):e2322203121. PubMed ID: 38968122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program.
    Kim DH; Sun D; Storck WK; Welker Leng K; Jenkins C; Coleman DJ; Sampson D; Guan X; Kumaraswamy A; Rodansky ES; Urrutia JA; Schwartzman JA; Zhang C; Beltran H; Labrecque MP; Morrissey C; Lucas JM; Coleman IM; Nelson PS; Corey E; Handelman SK; Sexton JZ; Aggarwal R; Abida W; Feng FY; Small EJ; Spratt DE; Bankhead A; Rao A; Gesner EM; Attwell S; Lakhotia S; Campeau E; Yates JA; Xia Z; Alumkal JJ
    Clin Cancer Res; 2021 Sep; 27(17):4923-4936. PubMed ID: 34145028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment and characterization of a novel treatment-related neuroendocrine prostate cancer cell line KUCaP13.
    Okasho K; Mizuno K; Fukui T; Lin YY; Kamiyama Y; Sunada T; Li X; Kimura H; Sumiyoshi T; Goto T; Kobayashi T; Lin D; Wang Y; Collins CC; Inoue T; Ogawa O; Akamatsu S
    Cancer Sci; 2021 Jul; 112(7):2781-2791. PubMed ID: 33960594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.